- This event has passed.
Neurology Clinical Trials Are Failing. How Can We Fix Them?
One billion people worldwide suffer from neurological related disorders with limited therapy options. Over 2000 neurological clinical trials start each year in the US alone. Yet, it is estimated that only 5.9% of Phase I neurology drugs are likely to get FDA approval.
Research innovation such as new biomarkers or advanced algorithms often do not get translated into clinical practice, slowing progress. Adding to that, the scale, inefficiency and subjectivity of neurological clinical trials makes them inherently difficult. Neuroimaging analysis is key to developing new therapies for brain disease but it’s difficult to do.
Join us for a discussion and audience Q&A hosted by QMENTA CEO, Vesna Prčkovska. Hear from our esteemed panel of experts who work across the life sciences research, development and care spectrum how clinical research leaders can take key steps now to transform the way they conduct neuroimaging based clinical trials to position them for success. Seats are limited so register now.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.